SNCA and Parkinson disease: However, in evaluating the relationship between plasma pS129-α-synuclein concentrations and various levels of cognitive ability among patients with PD, the plasma pS129-α-synuclein levels did not significantly differ between patients with varying severity of cognitive dysfunction (Figure 3C, p = 0.75).